Goldman Sachs
ALLO icon

Goldman Sachs’s Allogene Therapeutics ALLO Stock Holding History

Goldman Sachs’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.75M Buy
2,766,244
+476,786
+21% +$956K ﹤0.01% 3409
2025
Q4 		$3.14M Buy
2,289,458
+1,085,750
+90% +$1.43M ﹤0.01% 4188
2025
Q3 		$1.49M Sell
1,203,708
-4,299,433
-78% -$5.13M ﹤0.01% 4729
2025
Q2 		$6.22M Sell
5,503,141
-350,833
-6% -$466K ﹤0.01% 3202
2025
Q1 		$8.55M Buy
5,853,974
+3,747,397
+178% +$7.06M ﹤0.01% 2843
2024
Q4 		$4.49M Sell
2,106,577
-56,026
-3% -$138K ﹤0.01% 3553
2024
Q3 		$6.06M Buy
2,162,603
+632,556
+41% +$1.69M ﹤0.01% 3174
2024
Q2 		$3.57M Buy
1,530,047
+235,401
+18% +$694K ﹤0.01% 3469
2024
Q1 		$5.79M Sell
1,294,646
-2,042,568
-61% -$8.52M ﹤0.01% 2959
2023
Q4 		$10.7M Buy
3,337,214
+1,929,258
+137% +$5.47M ﹤0.01% 2461
2023
Q3 		$4.46M Sell
1,407,956
-92,016
-6% -$403K ﹤0.01% 3088
2023
Q2 		$7.45M Buy
1,499,972
+345,447
+30% +$1.87M ﹤0.01% 2739
2023
Q1 		$5.7M Sell
1,154,525
-463,600
-29% -$2.97M ﹤0.01% 2938
2022
Q4 		$10.2M Sell
1,618,125
-781,458
-33% -$7.23M ﹤0.01% 2573
2022
Q3 		$25.9M Buy
2,399,583
+424,626
+22% +$5.77M 0.01% 1628
2022
Q2 		$22.5M Sell
1,974,957
-987,252
-33% -$8.76M 0.01% 1805
2022
Q1 		$27M Buy
2,962,209
+1,138,944
+62% +$11.9M 0.01% 1805
2021
Q4 		$27.2M Sell
1,823,265
-156,447
-8% -$2.76M 0.01% 1847
2021
Q3 		$50.9M Buy
1,979,712
+264,325
+15% +$6.28M 0.01% 1274
2021
Q2 		$44.7M Buy
1,715,387
+434,309
+34% +$12.4M 0.01% 1359
2021
Q1 		$45.2M Sell
1,281,078
-108,588
-8% -$3.66M 0.01% 1245
2020
Q4 		$35.1M Buy
1,389,666
+548,316
+65% +$17.9M 0.01% 1407
2020
Q3 		$31.7M Buy
841,350
+586,883
+231% +$22.1M 0.01% 1365
2020
Q2 		$10.9M Buy
254,467
+67,739
+36% +$2.45M ﹤0.01% 2200
2020
Q1 		$3.63M Buy
186,728
+11,594
+7% +$276K ﹤0.01% 2883
2019
Q4 		$4.55M Buy
175,134
+69,888
+66% +$1.92M ﹤0.01% 3034
2019
Q3 		$2.87M Buy
105,246
+26,474
+34% +$754K ﹤0.01% 3285
2019
Q2 		$2.12M Buy
78,772
+15,561
+25% +$434K ﹤0.01% 3501
2019
Q1 		$1.83M Buy
63,211
+1,924
+3% +$55.8K ﹤0.01% 3699
2018
Q4 		$1.65M Buy
+61,287
New +$1.63M ﹤0.01% 3651

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs's ALLO Position: Q1 2026 in Review

Goldman Sachs increased its Allogene Therapeutics (ALLO) stake by 21% in Q1 2026, buying an estimated $956K and bringing the position to 2,766,244 shares worth $6.75M. The position accounts for ﹤0.01% of the portfolio, ranked #3409.

Goldman Sachs first reported a position in ALLO in Q4 2018 and has held it in 30 quarters since. The position peaked at $50.9M in Q3 2021. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Goldman Sachs held 2,766,244 shares of Allogene Therapeutics worth $6.75M as of Q1 2026.
  • Goldman Sachs bought 476,786 Allogene Therapeutics shares in Q1 2026, an estimated $956K.
  • Allogene Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3409 holding.
  • Goldman Sachs first reported a position in Allogene Therapeutics in Q4 2018 and has held it in 30 quarters since.
  • Goldman Sachs's Allogene Therapeutics position peaked at $50.9M in Q3 2021.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.